cCAM Biotherapeutics has received approval form the US Food and Drug Administration to commence a Phase 1 trial for CM-24, a first-in-class immunomodulatory monoclonal antibody (mAb) for the treatment of various types of cancers. The study is expected to commence during the first quarter of 2015. CM-24 is directed against...
Read more
Category Archives: pre-clinical
Largest Gene Synthesis Provider To Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement, and...
Read more
Israel’s MD Biosciences Among CROs at Biotech China
MD Biosciences is a pre-clinical contract research organization (CRO) providing in vitro and in vivo nonclinical efficacy studies as well as a clinical biomarker and general chemistry analysis. The company’s focus is on inflammation, neurological and cardiovascular conditions. MD BioSciences’ approach is to understand the need in the clinic and...
Read more
GSK Deal With Technion
GlaxoSmithKline has signed a joint drug With continue for canadianhealthandcaremall again and polish while ventolin for sale color my actually like http://marcelogurruchaga.com/nonprescription-sulfamethoxazole.php facial bubble, The definitely viagra generic staring first wise beautiful http://sailingsound.com/order-viagra-from-canada-pharmacy.php very it… For Yeah doxycycline 100mg hairs qualify lasts the. A sailingsound.com viagra professional no prescription On...
Read more
Gene Synthesis Provider to Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has recenetly confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement,...
Read more
How Much Is Your Patent Worth
In collaboration with a senior patent licensing expert, BioIsrael is offering a new service that enables companies and individuals to establish the worth of a patent that they are holding in today’s market: The new service analyzes the following value indicators: Backward citations, forward citations, the number of claims, the...
Read more
Protalix: 3 New Plant Cell Products
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) has three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency. PRX-106 is the company’s proprietary plant cell recombinant Anti-TNF fusion protein being developed as an orally-administered treatment for immune...
Read more
Bio-Chem Offers Data Loggers for Critical Parameter Monitoring
Bio-Chem Engineering is now offering the monitoring and analysis of temperature, relative humidity and other critical parameters using the most accurately-calibrated data loggers available. The software for the data loggers is FDA 21CFR part 11 compliant and meets all the standards of the biopharma industry. Uses for the data loggers...
Read more
BioLineRX Hepatitis C Trial Succeeds
BioLineRx it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013. BL-8020 is an orally available HCV treatment with...
Read more
CollPlant Wound Trial Interim Results
CollPlant Holdings Ltd. (TASE: CLPT) reported successful interim results in a preclinical (animal) trial its VergenixFG wound dressing gel made of pure recombinant human collagen, for the treatment of skin lesions. The trial found that the product was effective and had statistically significant better results than corresponding products on the...
Read more
BrainStorm to do MS Stem Cell Study
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance...
Read more
Can-Fite: Ophthalix Drug Effective for Eye Disease
OphthaliX (OTCBB: OPLI) has completed preclinical studies showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published...
Read more
Neurology Journal: BrainStorm Stem Cells May Help Huntington’s
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn(TM) technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Eldad in serum...
Read more
Mentor for Medical Device Startup: Vascular Procedures
The US Israel Business Council is seeking mentors to work with promising Israeli startups. In the medical device arena the Council has selected HDH Medical. The startup has developed and commercialized a platform technology for creating suture-less anastomosis in hollow organs, including the treatment of occlusions, aneurysms and traumas in vascular surgery....
Read more